<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid/><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid">PMC5683343</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid-ver">PMC5683343.1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaid">5683343</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaiid">5683343</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">29159043</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1016/j.nicl.2017.10.022</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">S2213-1582(17)30264-4</article-id></all-ids><extracted-table><table-id>t0005</table-id><table-label>Table 1</table-label><table-caption>Summary of ligand-based PET findings in DS and AD.</table-caption><table-wrap-foot>Abbreviations: AD, Alzheimer's disease; DS, Down syndrome; FDDNP, 2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-naphthyl}-ethylidene)malononitrile; PiB, Pittsburgh compound B.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="t0005" position="float" orientation="portrait"><label>Table 1</label><caption><p>Summary of ligand-based PET findings in DS and AD.</p></caption><alt-text id="al0005">Table 1.</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Authors</th><th colspan="1" rowspan="1">Final # of participants</th><th colspan="1" rowspan="1">Ligand; reference region</th><th colspan="1" rowspan="1">Results</th><th colspan="1" rowspan="1">Scanning feasibility issues</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><xref rid="bb0175" ref-type="bibr">Landt et al. (2011)</xref></td><td colspan="1" rowspan="1">5 with DS/AD, 4 with DS only, 14 healthy controls without DS</td><td colspan="1" rowspan="1">PiB; Cerebellum</td><td colspan="1" rowspan="1">Only people with DS older than 45 had significant binding in regions of interest, whether or not they had dementia.</td><td colspan="1" rowspan="1">1/11 (9.1%) DS participants who agreed to undergo scanning dropped out due to anxiety provoked by elevation of scanning table.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0250" ref-type="bibr">Nelson et al. (2011)</xref></td><td colspan="1" rowspan="1">19 with DS, 10 with AD, 10 controls</td><td colspan="1" rowspan="1">[18F]FDDNP; Cerebellum</td><td colspan="1" rowspan="1">Higher binding in DS (in parietal, medial temporal, lateral temporal, and frontal lobes and posterior cingulate gyrus), comparable or higher than AD group in all regions. Binding had positive association with age and behavioural dysfunction in several regions.</td><td colspan="1" rowspan="1">None reported.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0125" ref-type="bibr">Handen et al. (2012)</xref></td><td colspan="1" rowspan="1">7 with DS and no dementia</td><td colspan="1" rowspan="1">PiB; Cerebellum</td><td colspan="1" rowspan="1">The two subjects with PiB binding showed early striatal accumulation.</td><td colspan="1" rowspan="1">1/8 (12.5%) participants was unable to complete PET imaging (reason not provided).</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0130" ref-type="bibr">Hartley et al. (2014)</xref></td><td colspan="1" rowspan="1">63 with DS and no dementia</td><td colspan="1" rowspan="1">PiB; Subcortical white matter and cerebellum</td><td colspan="1" rowspan="1">Positive correlation between binding and age. No relationship between binding and cognitive measures when controlling for age (except for negative correlation with Rivermead Picture Recognition score when binding considered as continuous variable).</td><td colspan="1" rowspan="1">None for PET. In 9/63 scans (14.3%), T1 MRI failed due to motion artefact; An additional 2/54 (3.7%) did not have T2 acquisition.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0160" ref-type="bibr">Jennings et al. (2015)</xref></td><td colspan="1" rowspan="1">39 with DS, 2 of which had dementia</td><td colspan="1" rowspan="1">Florbetaben; Cerebellum</td><td colspan="1" rowspan="1">Uptake was correlated with age and was seen in people without AD.</td><td colspan="1" rowspan="1">None reported.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0285" ref-type="bibr">Rafii et al. (2015)</xref></td><td colspan="1" rowspan="1">12 with DS and no dementia</td><td colspan="1" rowspan="1">Florbetapir, Cerebellum</td><td colspan="1" rowspan="1">Amyloid load was associated with hippocampal atrophy. There was an inverse relationship between regional binding and glucose metabolism. No relationship between amyloid load and cognitive measures.</td><td colspan="1" rowspan="1">None reported.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0305" ref-type="bibr">Sabbagh et al. (2015)</xref></td><td colspan="1" rowspan="1">5 with DS and AD, 12 with DS only, 9 normal controls</td><td colspan="1" rowspan="1">Florbetapir; Pons</td><td colspan="1" rowspan="1">DS/AD had the highest uptake, followed by DS only. Age-related increases in binding were greater in DS group.</td><td colspan="1" rowspan="1">1/5 (20%) DS/AD+ subjects had severe impairment and was too agitated to obtain quality MRI/PET; 1/12 (8.3%) DS/AD- withdrew after PET and did not complete MRI (reason not provided).</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0005" ref-type="bibr">Annus et al. (2016)</xref></td><td colspan="1" rowspan="1">49 with DS (10 of which had dementia and 6 had cognitive decline)</td><td colspan="1" rowspan="1">PiB; Cerebellum</td><td colspan="1" rowspan="1">Binding begins in striatum around age 40, and was associated with dementia and cognitive decline.</td><td colspan="1" rowspan="1">None reported (most fell asleep during scan).</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0080" ref-type="bibr">Cole et al. (2017)</xref></td><td colspan="1" rowspan="1">46 with DS (9 of which had dementia and 6 with cognitive decline), 30 controls</td><td colspan="1" rowspan="1">PiB; Cerebellum</td><td colspan="1" rowspan="1">PiB was associated with brain aging. No relationship between PiB and cognitive score directly, but within the PiB positive group there was a relationship between brain age and cognitive score.</td><td colspan="1" rowspan="1">None reported.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0180" ref-type="bibr">Lao et al. (2016)</xref></td><td colspan="1" rowspan="1">68 with DS and no dementia</td><td colspan="1" rowspan="1">PiB, Cerebellum</td><td colspan="1" rowspan="1">Positive correlation between binding and age, particularly in the striatum.</td><td colspan="1" rowspan="1">1/72 (1.4%) excluded for being unable to complete PET scan; 1/72 (1.4%) excluded for no TI MRI scan (reasons not provided).</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0185" ref-type="bibr">Lao et al. (2017)</xref></td><td colspan="1" rowspan="1">52 with DS and no dementia</td><td colspan="1" rowspan="1">PiB; Cerebellum</td><td colspan="1" rowspan="1">Binding occurred first in the striatum, and rate of change in uptake was correlated to pre-existing amyloid. This happened before evidence of dementia or atrophy.</td><td colspan="1" rowspan="1">None reported.</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: AD, Alzheimer's disease; DS, Down syndrome; FDDNP, 2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-naphthyl}-ethylidene)malononitrile; PiB, Pittsburgh compound B.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Summary of ligand-based PET findings in DS and AD.</div>Table 1.<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Authors</th><th>Final # of participants</th><th>Ligand; reference region</th><th>Results</th><th>Scanning feasibility issues</th></tr></thead><tbody><tr><td>???</td><td>5 with DS/AD, 4 with DS only, 14 healthy controls without DS</td><td>PiB; Cerebellum</td><td>Only people with DS older than 45 had significant binding in regions of interest, whether or not they had dementia.</td><td>1/11 (9.1%) DS participants who agreed to undergo scanning dropped out due to anxiety provoked by elevation of scanning table.</td></tr><tr><td>???</td><td>19 with DS, 10 with AD, 10 controls</td><td>[18F]FDDNP; Cerebellum</td><td>Higher binding in DS (in parietal, medial temporal, lateral temporal, and frontal lobes and posterior cingulate gyrus), comparable or higher than AD group in all regions. Binding had positive association with age and behavioural dysfunction in several regions.</td><td>None reported.</td></tr><tr><td>???</td><td>7 with DS and no dementia</td><td>PiB; Cerebellum</td><td>The two subjects with PiB binding showed early striatal accumulation.</td><td>1/8 (12.5%) participants was unable to complete PET imaging (reason not provided).</td></tr><tr><td>???</td><td>63 with DS and no dementia</td><td>PiB; Subcortical white matter and cerebellum</td><td>Positive correlation between binding and age. No relationship between binding and cognitive measures when controlling for age (except for negative correlation with Rivermead Picture Recognition score when binding considered as continuous variable).</td><td>None for PET. In 9/63 scans (14.3%), T1 MRI failed due to motion artefact; An additional 2/54 (3.7%) did not have T2 acquisition.</td></tr><tr><td>???</td><td>39 with DS, 2 of which had dementia</td><td>Florbetaben; Cerebellum</td><td>Uptake was correlated with age and was seen in people without AD.</td><td>None reported.</td></tr><tr><td>???</td><td>12 with DS and no dementia</td><td>Florbetapir, Cerebellum</td><td>Amyloid load was associated with hippocampal atrophy. There was an inverse relationship between regional binding and glucose metabolism. No relationship between amyloid load and cognitive measures.</td><td>None reported.</td></tr><tr><td>???</td><td>5 with DS and AD, 12 with DS only, 9 normal controls</td><td>Florbetapir; Pons</td><td>DS/AD had the highest uptake, followed by DS only. Age-related increases in binding were greater in DS group.</td><td>1/5 (20%) DS/AD+ subjects had severe impairment and was too agitated to obtain quality MRI/PET; 1/12 (8.3%) DS/AD- withdrew after PET and did not complete MRI (reason not provided).</td></tr><tr><td>???</td><td>49 with DS (10 of which had dementia and 6 had cognitive decline)</td><td>PiB; Cerebellum</td><td>Binding begins in striatum around age 40, and was associated with dementia and cognitive decline.</td><td>None reported (most fell asleep during scan).</td></tr><tr><td>???</td><td>46 with DS (9 of which had dementia and 6 with cognitive decline), 30 controls</td><td>PiB; Cerebellum</td><td>PiB was associated with brain aging. No relationship between PiB and cognitive score directly, but within the PiB positive group there was a relationship between brain age and cognitive score.</td><td>None reported.</td></tr><tr><td>???</td><td>68 with DS and no dementia</td><td>PiB, Cerebellum</td><td>Positive correlation between binding and age, particularly in the striatum.</td><td>1/72 (1.4%) excluded for being unable to complete PET scan; 1/72 (1.4%) excluded for no TI MRI scan (reasons not provided).</td></tr><tr><td>???</td><td>52 with DS and no dementia</td><td>PiB; Cerebellum</td><td>Binding occurred first in the striatum, and rate of change in uptake was correlated to pre-existing amyloid. This happened before evidence of dementia or atrophy.</td><td>None reported.</td></tr></tbody></table></div>Abbreviations: AD, Alzheimer's disease; DS, Down syndrome; FDDNP, 2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-naphthyl}-ethylidene)malononitrile; PiB, Pittsburgh compound B.</transformed-table></extracted-table><extracted-table><table-id>t0010</table-id><table-label>Table 2</table-label><table-caption>Summary of MRI findings in DS and AD.</table-caption><table-wrap-foot>Abbreviations: AD, Alzheimer's disease; CSF, cerebrospinal fluid; DS, Down syndrome; MRI, magnetic resonance imaging; PiB, Pittsburgh compound B.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="t0010" position="float" orientation="portrait"><label>Table 2</label><caption><p>Summary of MRI findings in DS and AD.</p></caption><alt-text id="al0010">Table 2.</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Authors</th><th colspan="1" rowspan="1">Final # of participants</th><th colspan="1" rowspan="1">Method</th><th colspan="1" rowspan="1">Results</th><th colspan="1" rowspan="1">Scanning feasibility issues</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><xref rid="bb0025" ref-type="bibr">Beacher et al. (2009)</xref></td><td colspan="1" rowspan="1">19 with DS and AD, 39 with DS only</td><td colspan="1" rowspan="1">T1 MRI with volumetric analysis</td><td colspan="1" rowspan="1">Smaller hippocampus, caudate, right amygdala and putamen, and greater CSF in people with DS and AD compared to DS alone.</td><td colspan="1" rowspan="1">None reported.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0270" ref-type="bibr">Powell et al. (2014)</xref></td><td colspan="1" rowspan="1">10 non-demented with DS, 10 with DS and dementia, 10 age-matched controls</td><td colspan="1" rowspan="1">Fractional anisotropy analysis from DTI</td><td colspan="1" rowspan="1">People with DS have decreased white matter integrity, particularly in the frontal tracts. Cognitive dysfunction is associated with white matter damage. Those with dementia and DS showed increased damage compared to those with DS alone.</td><td colspan="1" rowspan="1">4 out of 34 (11.8%) initial DS participants excluded due to fear of scan or motion.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0285" ref-type="bibr">Rafii et al. (2015)</xref></td><td colspan="1" rowspan="1">12 with DS and no dementia</td><td colspan="1" rowspan="1">T1 MRI with volumetric analysis</td><td colspan="1" rowspan="1">Amyloid load was associated with hippocampal atrophy. Grey matter changes can be detected before clinical dementia onset.</td><td colspan="1" rowspan="1">None reported.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0305" ref-type="bibr">Sabbagh et al. (2015)</xref></td><td colspan="1" rowspan="1">5 with DS and AD, 12 non-demented with DS, 9 normal controls</td><td colspan="1" rowspan="1">T1 MRI with volumetric analysis</td><td colspan="1" rowspan="1">Those with AD and DS show increased atrophy of the posterior cingulate, parietal, temporal and frontal regions compared to those with DS only.</td><td colspan="1" rowspan="1">1/5 (20%) DS/AD+ subjects had severe impairment and was too agitated to obtain quality MRI/PET; 1/12 (8.3%) DS/AD- withdrew after PET and did not complete MRI (reason not provided).</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0230" ref-type="bibr">Matthews et al. (2016)</xref></td><td colspan="1" rowspan="1">12 non-demented with DS</td><td colspan="1" rowspan="1">T1 MRI with volumetric analysis</td><td colspan="1" rowspan="1">MRI can demonstrate a varying degree of AD atrophy in non-demented DS subjects, and this has some correlation with cognitive measures and amyloid burden.</td><td colspan="1" rowspan="1">1/12 (8.3%) excluded from structural MRI analysis due to blur.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0335" ref-type="bibr">Wilson (2016)</xref></td><td colspan="1" rowspan="1">13 PiB negative with DS, 10 PiB positive with DS, 18 controls</td><td colspan="1" rowspan="1">Fractional anisotropy analysis from DTI</td><td colspan="1" rowspan="1">The PiB positive DS group showed decreased white matter integrity, particularly in the posterior tracts, compared to the other groups.</td><td colspan="1" rowspan="1">Lower IQ or a diagnosis of dementia was correlated with movement artefacts.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0010" ref-type="bibr">Annus et al. (2017)</xref></td><td colspan="1" rowspan="1">46 with DS (19 PiB positive, 27 PiB negative), 30 age-matched controls</td><td colspan="1" rowspan="1">T1 MRI with volumetric analysis</td><td colspan="1" rowspan="1">Posterior-dominant cortical thinning and atrophy of hippocampus, thalamus, and striatum in those with DS and amyloid.</td><td colspan="1" rowspan="1">3 out of 49 (6.1%) who underwent scanning were excluded due to motion artefact.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0100" ref-type="bibr">Fenoll et al. (2017)</xref></td><td colspan="1" rowspan="1">45 non-demented with DS, 45 matched controls</td><td colspan="1" rowspan="1">Fractional anisotropy analysis from DTI</td><td colspan="1" rowspan="1">People with DS have decreased white matter integrity compared to controls, especially in frontal-subcortical circuits, but age-related white matter changes are not accelerated in DS.</td><td colspan="1" rowspan="1">18 out of 63 (28.6%) who underwent scanning were excluded due to motion artefact.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0185" ref-type="bibr">Lao et al. (2017)</xref></td><td colspan="1" rowspan="1">52 with DS and no dementia</td><td colspan="1" rowspan="1">T1 MRI with volumetric analysis</td><td colspan="1" rowspan="1">Amyloid accumulation occurs prior to dementia onset or grey matter volume reduction.</td><td colspan="1" rowspan="1">None reported.</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: AD, Alzheimer's disease; CSF, cerebrospinal fluid; DS, Down syndrome; MRI, magnetic resonance imaging; PiB, Pittsburgh compound B.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Summary of MRI findings in DS and AD.</div>Table 2.<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Authors</th><th>Final # of participants</th><th>Method</th><th>Results</th><th>Scanning feasibility issues</th></tr></thead><tbody><tr><td>???</td><td>19 with DS and AD, 39 with DS only</td><td>T1 MRI with volumetric analysis</td><td>Smaller hippocampus, caudate, right amygdala and putamen, and greater CSF in people with DS and AD compared to DS alone.</td><td>None reported.</td></tr><tr><td>???</td><td>10 non-demented with DS, 10 with DS and dementia, 10 age-matched controls</td><td>Fractional anisotropy analysis from DTI</td><td>People with DS have decreased white matter integrity, particularly in the frontal tracts. Cognitive dysfunction is associated with white matter damage. Those with dementia and DS showed increased damage compared to those with DS alone.</td><td>4 out of 34 (11.8%) initial DS participants excluded due to fear of scan or motion.</td></tr><tr><td>???</td><td>12 with DS and no dementia</td><td>T1 MRI with volumetric analysis</td><td>Amyloid load was associated with hippocampal atrophy. Grey matter changes can be detected before clinical dementia onset.</td><td>None reported.</td></tr><tr><td>???</td><td>5 with DS and AD, 12 non-demented with DS, 9 normal controls</td><td>T1 MRI with volumetric analysis</td><td>Those with AD and DS show increased atrophy of the posterior cingulate, parietal, temporal and frontal regions compared to those with DS only.</td><td>1/5 (20%) DS/AD+ subjects had severe impairment and was too agitated to obtain quality MRI/PET; 1/12 (8.3%) DS/AD- withdrew after PET and did not complete MRI (reason not provided).</td></tr><tr><td>???</td><td>12 non-demented with DS</td><td>T1 MRI with volumetric analysis</td><td>MRI can demonstrate a varying degree of AD atrophy in non-demented DS subjects, and this has some correlation with cognitive measures and amyloid burden.</td><td>1/12 (8.3%) excluded from structural MRI analysis due to blur.</td></tr><tr><td>???</td><td>13 PiB negative with DS, 10 PiB positive with DS, 18 controls</td><td>Fractional anisotropy analysis from DTI</td><td>The PiB positive DS group showed decreased white matter integrity, particularly in the posterior tracts, compared to the other groups.</td><td>Lower IQ or a diagnosis of dementia was correlated with movement artefacts.</td></tr><tr><td>???</td><td>46 with DS (19 PiB positive, 27 PiB negative), 30 age-matched controls</td><td>T1 MRI with volumetric analysis</td><td>Posterior-dominant cortical thinning and atrophy of hippocampus, thalamus, and striatum in those with DS and amyloid.</td><td>3 out of 49 (6.1%) who underwent scanning were excluded due to motion artefact.</td></tr><tr><td>???</td><td>45 non-demented with DS, 45 matched controls</td><td>Fractional anisotropy analysis from DTI</td><td>People with DS have decreased white matter integrity compared to controls, especially in frontal-subcortical circuits, but age-related white matter changes are not accelerated in DS.</td><td>18 out of 63 (28.6%) who underwent scanning were excluded due to motion artefact.</td></tr><tr><td>???</td><td>52 with DS and no dementia</td><td>T1 MRI with volumetric analysis</td><td>Amyloid accumulation occurs prior to dementia onset or grey matter volume reduction.</td><td>None reported.</td></tr></tbody></table></div>Abbreviations: AD, Alzheimer's disease; CSF, cerebrospinal fluid; DS, Down syndrome; MRI, magnetic resonance imaging; PiB, Pittsburgh compound B.</transformed-table></extracted-table><extracted-table><table-id>t0015</table-id><table-label>Table 3</table-label><table-caption>Summary of EEG findings in DS and AD.</table-caption><table-wrap-foot>Abbreviations: AD, Alzheimer's disease; DS, Down syndrome; EEG, electroencephalography; EKG, electrocardiography; EMG, electromyography; EOG, electrooculography.</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="t0015" position="float" orientation="portrait"><label>Table 3</label><caption><p>Summary of EEG findings in DS and AD.</p></caption><alt-text id="al0015">Table 3:</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Authors</th><th colspan="1" rowspan="1"># of participants</th><th colspan="1" rowspan="1">Method</th><th colspan="1" rowspan="1">Findings</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><xref rid="bb0020" ref-type="bibr">Babiloni et al. (2010)</xref></td><td colspan="1" rowspan="1">45 DS subjects, 45 age-matched cognitively normal subjects</td><td colspan="1" rowspan="1">Eyes-closed resting EEG data collected, with EOG.</td><td colspan="1" rowspan="1">Central, parietal, occipital, and temporal cortex had alpha and beta rhythms with lower amplitude in DS, while delta rhythms were higher in amplitude in DS.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0265" ref-type="bibr">d'Orsi et al. (2014)</xref></td><td colspan="1" rowspan="1">12 with DS/AD/myoclonic epilepsy, over the age of 40</td><td colspan="1" rowspan="1">Long-term EEG monitoring during sleep and wake, with EMG and EKG.</td><td colspan="1" rowspan="1">3 stages of epilepsy were found: diffuse abnormalities during sleep with dementia onset, myoclonic epilepsy, and finally non-epileptic myoclonus with severe dementia.</td></tr><tr><td colspan="1" rowspan="1"><xref rid="bb0310" ref-type="bibr">Salem et al. (2015)</xref></td><td colspan="1" rowspan="1">21 with DS and dementia, 16 with DS and no dementia</td><td colspan="1" rowspan="1">EEG during wake resting state, with EOG and EKG.</td><td colspan="1" rowspan="1">Decreased theta band frequencies in several regions of the brain are correlated with cognitive deterioration based on the Dementia Screening Questionnaire in Intellectual Disability.</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: AD, Alzheimer's disease; DS, Down syndrome; EEG, electroencephalography; EKG, electrocardiography; EMG, electromyography; EOG, electrooculography.</p></fn></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Summary of EEG findings in DS and AD.</div>Table 3:<div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Authors</th><th># of participants</th><th>Method</th><th>Findings</th></tr></thead><tbody><tr><td>???</td><td>45 DS subjects, 45 age-matched cognitively normal subjects</td><td>Eyes-closed resting EEG data collected, with EOG.</td><td>Central, parietal, occipital, and temporal cortex had alpha and beta rhythms with lower amplitude in DS, while delta rhythms were higher in amplitude in DS.</td></tr><tr><td>???</td><td>12 with DS/AD/myoclonic epilepsy, over the age of 40</td><td>Long-term EEG monitoring during sleep and wake, with EMG and EKG.</td><td>3 stages of epilepsy were found: diffuse abnormalities during sleep with dementia onset, myoclonic epilepsy, and finally non-epileptic myoclonus with severe dementia.</td></tr><tr><td>???</td><td>21 with DS and dementia, 16 with DS and no dementia</td><td>EEG during wake resting state, with EOG and EKG.</td><td>Decreased theta band frequencies in several regions of the brain are correlated with cognitive deterioration based on the Dementia Screening Questionnaire in Intellectual Disability.</td></tr></tbody></table></div>Abbreviations: AD, Alzheimer's disease; DS, Down syndrome; EEG, electroencephalography; EKG, electrocardiography; EMG, electromyography; EOG, electrooculography.</transformed-table></extracted-table></extracted-tables-set>